These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 33748900)

  • 1. The outcomes of three-factor prothrombin complex concentrate (3F-PCC) in warfarin anticoagulation reversal: a prospective, single-arm, open-label, multicentre study.
    Koh HP; Jagan N; George D; Mazlan-Kepli W; Mohamed S; Lim HT; Ross NT; Mazlan AM
    J Thromb Thrombolysis; 2021 Oct; 52(3):836-847. PubMed ID: 33748900
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the safety and efficacy between 3-factor and 4-factor prothrombin complex concentrates for the reversal of warfarin.
    Kuroski JE; Young S
    Am J Emerg Med; 2017 Jun; 35(6):871-874. PubMed ID: 28161220
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protocolized warfarin reversal with 4-factor prothrombin complex concentrate versus 3-factor prothrombin complex concentrate with recombinant factor VIIa.
    Barton CA; Hom M; Johnson NB; Case J; Ran R; Schreiber M
    Am J Surg; 2018 May; 215(5):775-779. PubMed ID: 29338845
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of Warfarin Reversal with 4-Factor Prothrombin Complex Concentrate Compared to 3-Factor Prothrombin Complex Concentrate at a Tertiary Academic Medical Center.
    Al-Majzoub O; Rybak E; Reardon DP; Krause P; Connors JM
    J Emerg Med; 2016 Jan; 50(1):7-13. PubMed ID: 26433428
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is there a difference in efficacy, safety, and cost-effectiveness between 3-factor and 4-factor prothrombin complex concentrates among trauma patients on oral anticoagulants?
    Mangram A; Oguntodu OF; Dzandu JK; Hollingworth AK; Hall S; Cung C; Rodriguez J; Yusupov I; Barletta JF
    J Crit Care; 2016 Jun; 33():252-6. PubMed ID: 27021851
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of four-factor prothrombin complex concentrate fixed, weight-based dosing for reversal of warfarin anticoagulation.
    Endres K; St Bernard R; Chin-Yee I; Hsia C; Lazo-Langner A
    Hematology; 2020 Dec; 25(1):489-493. PubMed ID: 33317427
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prothrombin complex concentrates used alone in urgent reversal of warfarin anticoagulation.
    Tran H; Collecutt M; Whitehead S; Salem HH
    Intern Med J; 2011 Apr; 41(4):337-43. PubMed ID: 20403070
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Three- versus four-factor prothrombin complex concentrate for the reversal of warfarin-induced bleeding.
    Holt T; Taylor S; Abraham P; Mcmillian W; Harris S; Curtis J; Elder T
    Int J Crit Illn Inj Sci; 2018; 8(1):36-40. PubMed ID: 29619338
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of timing and dosing of four-factor prothrombin complex concentrate administration on outcomes in warfarin-associated intracranial hemorrhage.
    Cicci CD; Weiss A; Dang C; Stanton M; Feldman R
    Pharmacotherapy; 2022 May; 42(5):366-374. PubMed ID: 35384000
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emergent reversal of vitamin K antagonists: addressing all the factors.
    Martin DT; Barton CA; Dodgion C; Schreiber M
    Am J Surg; 2016 May; 211(5):919-25. PubMed ID: 27046797
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Obesity increases risk of anticoagulation reversal failure with prothrombin complex concentrate in those with intracranial hemorrhage.
    Chu C; Tokumaru S; Izumi K; Nakagawa K
    Int J Neurosci; 2016; 126(1):62-6. PubMed ID: 25430740
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Propensity score adjusted comparison of three-factor versus four-factor prothrombin complex concentrate for emergent warfarin reversal: a retrospective cohort study.
    Margraf DJ; Seaburg S; Beilman GJ; Wolfson J; Gipson JC; Chapman SA
    BMC Emerg Med; 2020 Nov; 20(1):93. PubMed ID: 33243152
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative effectiveness of 3- versus 4-factor prothrombin complex concentrate for emergent warfarin reversal.
    Voils SA; Holder MC; Premraj S; Catlin JR; Allen BR
    Thromb Res; 2015 Sep; 136(3):595-8. PubMed ID: 26233569
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discussion of "Protocolized warfarin reversal with 4-factor prothrombin complex concentrate versus 3-factor prothrombin complex concentrate with recombinant factor VIIa".
    Van Dusen R
    Am J Surg; 2018 May; 215(5):780-781. PubMed ID: 29366484
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inactivated Four-Factor Prothrombin Complex Concentrate Dosing Practices for Reversal of Warfarin-Related Intracranial Hemorrhage.
    Rhoney DH; La M; Merz M; Cook A; Owusu KA; Roels C; Blunck J; Shewmaker J; Sangha KS; Farrokh S; Lewin J; Chester KW; Human T; Bledsoe K; Greene K; Levesque M; Rocker JC; Davis G; Neyens R; Lassiter TF; Adriance SM
    Neurocrit Care; 2021 Aug; 35(1):130-138. PubMed ID: 33219462
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of 3 Different Prothrombin Complex Concentrate Regimens for Emergent Warfarin Reversal: PCCWaR Study.
    Dietrich SK; Rowe S; Cocchio CA; Harmon AJ; Nerenberg SF; Blankenship PS
    Ann Pharmacother; 2021 Aug; 55(8):980-987. PubMed ID: 33305592
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of 3-Factor Versus 4-Factor Prothrombin Complex Concentrate With Regard to Warfarin Reversal, Blood Product Use, and Costs.
    DeAngelo J; Jarrell D; Cosgrove R; Camamo J; Edwards C; Patanwala AE
    Am J Ther; 2018; 25(3):e326-e332. PubMed ID: 28763307
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prospective Evaluation of a Fixed-Dose 4-Factor Prothrombin Complex Concentrate Protocol for Urgent Vitamin K Antagonist Reversal.
    Bitonti MT; Rumbarger RL; Absher RK; Curran LM
    J Emerg Med; 2020 Feb; 58(2):324-329. PubMed ID: 31787372
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prothrombin complex concentrates to reverse warfarin-induced coagulopathy in patients with intracranial bleeding.
    Cabral KP; Fraser GL; Duprey J; Gibbons BA; Hayes T; Florman JE; Seder DB
    Clin Neurol Neurosurg; 2013 Jun; 115(6):770-4. PubMed ID: 22835715
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of modified fixed dose four-factor prothrombin complex concentrate for warfarin reversal.
    Peterson ME; Jaynes MP; Berardi S; Morton C
    J Thromb Thrombolysis; 2024 Jun; 57(5):865-870. PubMed ID: 38581551
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.